ChemDiv
ChemDiv is a privately held, San Diego-headquartered drug discovery solutions provider offering 1.6 million screening compounds, a 1B virtual chemical space, proprietary AI/ML discovery tools, and integrated Target ID through Clinical POC services to pharmaceutical, biotech, academic, and screening-center customers globally.
- Company typePrivate
- Founded1994
- HeadquartersSan Diego, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What ChemDiv does
ChemDiv Inc. is a privately held, San Diego-headquartered drug discovery solutions provider founded in 1994, serving pharmaceutical, biotechnology, academic, and screening-center customers in the US, Europe, and Asia. The company operates a 501-1,000 person organization with regional representative offices in South Korea, Japan, and China, offering both a transactional compound catalog and a full-service integrated discovery platform.
The company's core offering combines a physical and virtual chemical inventory—1.6 million stock-available screening compounds, 12 million units of managed global inventory, 75,000+ building blocks, 45,000+ inhibitors, 114 predesigned focused libraries, and 2 trillion synthetically feasible structures—with a hybrid AI/ML drug discovery platform curated by scientists. Proprietary tools include GPU-accelerated 3D docking (CombiRIDGE), in-situ conformer generation (GINGER), the Rapid Isostere Discovery Engine (RIDE), AI Kinome Profiling, in silico CADD services, and validated AI/ML training datasets. The integrated services workflow spans Target ID, Lead Discovery, Lead Optimization, IND-enabling studies, FIM studies, and Clinical Proof of Concept, supported by medicinal chemistry, discovery biology, ADME/DMPK, in vivo models, safety/toxicology, and CMC capabilities.
ChemDiv generates revenue through three streams: (1) one-time per-compound sales of screening compounds and libraries via its chemdiv.com e-commerce storefront and direct outreach; (2) professional-services contracts for integrated end-to-end drug discovery engagements with named partners such as Mondego Bio, Polku Therapeutics, Brenig Therapeutics, Traws Pharma, and Barinthus Biotherapeutics; and (3) CMC services. Pricing is quote-based and not publicly disclosed, with deep partnerships spanning CNS, oncology, infectious disease, and cardiometabolic indications across 200+ validated partner laboratories.
ChemDiv firmographics
Firmographics- Name
- ChemDiv
- Legal name
- ChemDiv Inc.
- Website
- https://chemdiv.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- ChemDiv is a privately held, San Diego-headquartered drug discovery solutions provider offering 1.6 million screening compounds, a 1B virtual chemical space, proprietary AI/ML discovery tools, and integrated Target ID through Clinical POC services to pharmaceutical, biotech, academic, and screening-center customers globally.
- Ownership category
- akta.pro rank
ChemDiv industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Chemicals & Allied Products (2800)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM), Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where ChemDiv is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
ChemDiv business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Screening Compound and Library Sales: Sale of 1.6 million stock available screening compounds, focused/targeted libraries, diversity libraries, preplated libraries, building blocks (75K+), inhibitors and approved drugs (45K+), and natural compounds. Customers can purchase online through the e-commerce platform with compounds available in various formats (dry powders, DMSO solutions, 96/384-well plates).
- Integrated Drug Discovery Services: Full-service drug discovery including target ID, lead discovery, lead optimization, synthetic and medicinal chemistry, discovery biology, ADME/DMPK, in vivo/ex vivo models, safety and toxicology, and clinical proof of concept studies. Services support partners like Polku Therapeutics, Brenig Therapeutics, and Mondego Bio.
- CMC Services: Chemistry, Manufacturing and Controls services including manufacturing, medicinal chemistry, and predictive pharmacology services for clinical and regulatory progress. Extended collaboration with Traws Pharma for ratutrelvir COVID-19 therapeutic.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for screening compound libraries |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
ChemDiv product offering
Product offeringCore offering
ChemDiv fundamentally provides integrated drug discovery solutions comprising a catalog of 1.6 million stock-available screening compounds, 100+ focused and targeted libraries, a 75,000+ building blocks collection, and a 1 billion virtual chemical space, sold alongside end-to-end discovery services spanning target identification, lead discovery, lead optimization, ADME/DMPK, in vivo models, safety/toxicology, CMC manufacturing, and clinical proof of concept, all supported by a proprietary AI/ML platform and GPU-accelerated computational tools.
Product overview
ChemDiv is a global provider of integrated drug discovery solutions offering a comprehensive portfolio of screening compounds, chemical libraries, and discovery services. The core offering consists of the Screening Compounds Catalog (1.6M compounds) and Screening Libraries (100+ focused/targeted libraries organized by therapeutic areas and target families), supported by a Building Blocks Collection (75K compounds) and Virtual Chemical Space (1B virtual compounds). The service platform encompasses Integrated Drug Discovery Services spanning Target ID through Clinical POC, AI-driven capabilities (AI Kinome Profile, AI/ML Datasets), CMC Services, and specialized technology features (CombiRIDGE, In-situ GINGER, RIDE) for virtual screening and compound generation. The company has over 32 years of experience completing hundreds of leads, candidates, and new drug programs for pharma, biotech, and academic partners globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Screening Compounds Catalog Online catalog of 1.6 million stock-available screening compounds offered for purchase in multiple formats (dry powders, DMSO solutions, 96/384-well plates) by pharmaceutical, biotech, and academic buyers for hit identification and screening campaigns.
- Screening Libraries Over 100 pre-designed focused and targeted compound libraries, plus 17 annotated libraries with bioactivity data, covering therapeutic areas, target families, and mechanisms of action for pharma, biotech, and academic screening programs.
- Building Blocks Collection 75,000 stock-available building blocks for medicinal chemistry projects, combinatorial library generation, and hit-to-lead optimization, with NMR and LC-MS quality control and >90% purity guarantee.
- Virtual Chemical Space 1 billion virtual compound library validated and built upon commercially available anchors, building blocks, and cores, with 2D fingerprint and substructure search and GPU-accelerated virtual screening for hit identification and lead generation.
- AI Kinome Profile AI-driven kinome-wide selectivity profiling service for drug discovery teams, providing comprehensive kinase target assessment using ChemDiv's proprietary datasets to support target identification and selectivity optimization.
- AI/ML Datasets Validated proprietary AI/ML training datasets with verified experimental data, balanced activity representation, standardized conditions, and comprehensive ADMET profiles, offered for ML-ready model training in drug discovery.
- Integrated Drug Discovery Services Full-spectrum drug discovery services covering target identification, lead discovery, lead optimization, IND-enabling studies, FIM studies, and clinical proof of concept, including medicinal chemistry, in silico CADD, discovery biology, ADME/DMPK, in vivo models, and safety/toxicology, for pharma and biotech partners.
- CMC Services Chemistry, Manufacturing and Controls (CMC) services including scale-up manufacturing, medicinal chemistry, predictive pharmacology, and regulatory progression support for clinical-stage development programs.
Quantifiable outcome
- Successfully completed hundreds of leads, candidates and new drug programs over 32 years
- +2 more outcomes
Companies that use ChemDiv
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles4 records
ChemDiv technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature8 records
ChemDiv partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Polku TherapeuticscoreLong-term collaboration leveraging ChemDiv's proprietary CNS-focused drug discovery platform for neurodegenerative disease programs. Polku Therapeutics reported positive efficacy results for lead compound POLK-38, demonstrating significant treatment effects on brain tau pathology and spatial learning in a PS19 tauopathy mouse model.
- Brenig TherapeuticscoreCollaboration using ChemDiv's CNS drug discovery platform for programs targeting LRRK2 and NLRP3 pathways, which have advanced into clinical development.
- Traws PharmacoreExtended CMC services collaboration supporting clinical development of ratutrelvir, an oral COVID-19 therapeutic in Phase 2 trials. Services include manufacturing, medicinal chemistry, and predictive pharmacology to support clinical and regulatory progress.
- Mondego BiocoreExtended partnership for best-in-class PTPN2 immuno-oncology program. Collaboration involves drug discovery, scale-up manufacturing, and accelerating clinical readiness, supported by facilities across Europe and the U.S.
- Clywedog Therapeutics (Barinthus Biotherapeutics)minorChemDiv continues providing R&D services support following Clywedog Therapeutics' merger with Barinthus Biotherapeutics. Barinthus is developing VTP-300 for hepatitis B and VTP-1000 for celiac disease using viral vector and synthetic platform technologies.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
ChemDiv competitors and assessment
Company assessmentDirect peers
- Evotec SE: Evotec is a global integrated drug discovery CRO offering target identification through clinical candidate services to pharma and biotech partners, with a similar end-to-end services model and AI-enabled platforms (e.g., EVOpanHunter). Direct overlap with ChemDiv in offering Target ID through IND-enabling workflows and library/design services.
- MedChemExpress (MCE): MedChemExpress is a major supplier of screening compounds, inhibitors, building blocks, and natural products to pharma, biotech, and academic researchers globally, with transparent online catalog pricing. Direct overlap with ChemDiv's catalog sales and self-service e-commerce model, though MCE is more catalog-focused and less service-heavy.
- Enamine Ltd. Enamine is a leading supplier of screening compounds, building blocks, and pre-plated libraries, and offers REAL Database virtual chemical space and custom synthesis. Direct overlap with ChemDiv's compound catalog, building blocks (75K+), and 1B virtual space offering, with comparable catalog-driven business model.
- Reaction Biology Corporation: Reaction Biology provides early-stage drug discovery services including compound screening, medicinal chemistry, and biology/protein production services to biotech and pharma. Comparable integrated discovery CRO model at smaller scale, with similar target customer profile.
- Tocris Bioscience (Bio-Techne): Tocris (a Bio-Techne brand) supplies high-purity small molecules, inhibitors, and tool compounds to neuroscience and other therapeutic-area researchers. Comparable in catalog chemical supply with quality focus, though more product-focused and less service-oriented than ChemDiv.
- Life Chemicals: Life Chemicals supplies screening compound libraries, building blocks, and custom synthesis services, with focus on focused/targeted libraries similar to ChemDiv's 114 predesigned libraries. Direct peer in the catalog and library supply segment with similar customer base in pharma/biotech screening.
Broad incumbents
- Eurofins Discovery: Eurofins Discovery offers integrated drug discovery services including compound libraries (e.g., Eurofins Discovery Services, PanLabs), in vitro pharmacology, ADME, and in vivo studies for pharma/biotech. Comparable integrated discovery footprint with established global scale.
- WuXi AppTec: WuXi AppTec operates a global discovery CRO platform (WuXi Biology, WuXi Chemistry) providing compound libraries, medicinal chemistry, DMPK, in vivo pharmacology, and CMC services to pharma and biotech. Comparable integrated discovery footprint, though at much larger scale and with broader capabilities including biologics.
- Charles River Laboratories: Charles River is a large, established CRO with a Discovery & Safety Assessment segment offering compound libraries, medicinal chemistry, in vitro/in vivo biology, and integrated discovery services to pharma/biotech. Overlaps with ChemDiv on library sales and integrated discovery, but operates at much larger scale with broader service portfolio.
Emerging players
- MolPort: MolPort operates a chemical sourcing marketplace aggregating compound inventories from multiple suppliers with online search and purchasing. Adjacent competitor in the compound procurement workflow; less focused on proprietary libraries and integrated services than ChemDiv but overlaps on catalog access for screening compounds.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
ChemDiv social profiles
Digital presenceChemDiv financial estimates
Financial estimateRevenue estimate
Valuation estimate
ChemDiv leadership team
Management profileNumber of profiles
Profiles2 records
ChemDiv funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ChemDiv M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ChemDiv
What does ChemDiv do?
ChemDiv fundamentally provides integrated drug discovery solutions comprising a catalog of 1.6 million stock-available screening compounds, 100+ focused and targeted libraries, a 75,000+ building blocks collection, and a 1 billion virtual chemical space, sold alongside end-to-end discovery services spanning target identification, lead discovery, lead optimization, ADME/DMPK, in vivo models, safety/toxicology, CMC manufacturing, and clinical proof of concept, all supported by a proprietary AI/ML platform and GPU-accelerated computational tools.
Is ChemDiv a public or private company?
ChemDiv is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was ChemDiv founded?
ChemDiv was founded in 1994. It employs 501 to 1,000 people.
Where is ChemDiv based?
ChemDiv is headquartered in San Diego, United States, in the North America region.
How does ChemDiv make money?
Three revenue lines are on record. Screening Compound and Library Sales are the primary driver. The others are integrated Drug Discovery Services and CMC Services.
Who are ChemDiv's main competitors?
Direct peers on record are Evotec SE, MedChemExpress (MCE), Enamine Ltd., Reaction Biology Corporation, Tocris Bioscience (Bio-Techne) and Life Chemicals. Broad incumbents are Eurofins Discovery, WuXi AppTec and Charles River Laboratories. MolPort is listed as an emerging player.
Does ChemDiv have an API?
No public API is recorded for ChemDiv.
What industry is ChemDiv in?
ChemDiv's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 2833.